Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone

16Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We have previously established the recommended phase II dose (RPTD) of ixabepilone as 40 mg/m2 administered over 1 h repeated every 3 weeks with neuropathy as a cumulative dose-limiting toxicity. We expanded the cohort at the RPTD to include detailed assessment of nerve damage in these patients. We report our findings on vibration perception threshold (VPT) and neuropathy. Patients and methods: Forty-four patients were treated with a median (range) of three (1-14) cycles of ixabepilone. The VPT (5-min duration) and nerve conduction test (NCT, 10-min duration) were carried out in the office, before ixabepilone dosing, and every two cycles thereafter. Results: Neuropathy (grade 1 and grades 2-3) was observed in 17 (38.6%) and 11 (25%) patients, respectively. The mean increase in VPT as a function of grade 0-1 versus grades 2-3 neuropathy was 0.235 ± 0.03 versus 0.869 ± 0.09 (P = 0.049) vibration units. The F-wave frequency and distal motor latency, as assessed using the NCT, did not correlate with clinical neurotoxicity. Conclusion: The change in VPT is observed early and likely reflects early vibration perception change. Mean change in VPT correlates with the severity of clinical neuropathy. Whether VPT change predicts onset of severe neuropathy warrants prospective testing and validation. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

References Powered by Scopus

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

547Citations
N/AReaders
Get full text

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

501Citations
N/AReaders
Get full text

Peripheral neuropathy induced by microtubule-stabilizing agents

423Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Chemotherapy-induced peripheral neurotoxicity

265Citations
N/AReaders
Get full text

Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)

219Citations
N/AReaders
Get full text

Chemotherapy-induced peripheral neuropathy: An unresolved issue

64Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Goel, S., Goldberg, G. L., Kuo, D. Y. S., Muggia, F., Arezzo, J., & Mani, S. (2008). Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. Annals of Oncology, 19(12), 2048–2052. https://doi.org/10.1093/annonc/mdn420

Readers' Seniority

Tooltip

Researcher 8

57%

PhD / Post grad / Masters / Doc 5

36%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Nursing and Health Professions 5

36%

Agricultural and Biological Sciences 4

29%

Medicine and Dentistry 3

21%

Biochemistry, Genetics and Molecular Bi... 2

14%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 43

Save time finding and organizing research with Mendeley

Sign up for free